Navigation Links
El profesor e investigador mundial líder en cáncer, Paul Workman, se une a The Innovation Debate 2012
Date:11/20/2012

tiondebate.com. Todo el mundo tendrá la oportunidad de compartir sus visiones en torno a los retos vitales a los que se enfrenta la ciencia y la innovación que surgen por medio de The Innovation Debate y enviar su pregunta al panel de expertos. Si desea ver la emisión web en directo del debate desde las 4pm del 20 de noviembre de 2012, regístrese hoy en http://www.innovationdebate.com

Únase al debate ahora en http://www.innovationdebate.com y síganos en Twitter @Innovatedebate #innovationdebate

Acerca de Astellas Pharma Europe Ltd.

Astellas Pharma Europe Ltd., con sede en el Reino Unido, es una filial europea de Astellas Pharma Inc., una empresa con sede en Tokio. Astellas es una empresa farmacéutica dedicada a mejorar la salud de las personas de todo el mundo mediante el suministro de fármacos innovadores y fiables. La compañía tiene como objetivo convertirse en una empresa global que combine capacidades extraordinarias de I+D y marketing y continúe creciendo en el mercado mundial farmacéutico. Astellas Pharma Europe Ltd. es responsable de 21 empresas afiliadas situadas en Europa, Oriente Medio y África, una instalación de I+D y tres plantas de producción. La compañía cuenta con una plantilla de aproximadamente 4.300 empleados en estas regiones. Para más información sobre Astellas Pharma Europe, visite http://www.astellas.eu.

El Institute of Cancer Research, Londres, es uno de los institutos de investigación de cáncer más influyentes del mundo.

Los científicos y médicos del Institute of Cancer Research (ICR) trabajan todos los días con el fin de conseguir un impacto real en las vidas de los pacientes con cáncer. A través de su asociación única con The Roy
'/>"/>

SOURCE Innovation Debate
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Accelrys Materials Studio Release 6.1 Speeds Innovation with Enterprise Capabilities
2. Biobetters in Key Markets - Opportunities for Biotechnology Companies to Sustain Innovation with Low Risk and High Value Offerings
3. SomaGenics Announces Issue of Key Patent for Its sshRNA Technology and Receipt of Two New Small Business Innovation NIH Grants
4. Centers for Medicare & Medicaid Services Win 2012 National Cybersecurity Innovation Award
5. ABTCP: Internationale Krise beeinflusst den Papier- und Zellstoffmarkt, doch Brasilien investiert weiterhin in Innovationen
6. New Report: "Innovations in Drug Delivery - Broad-based Proprietary Technology Platforms to Address Delivery Efficiency and Improve Patient Compliance" Now Available at Twease.org
7. Elsevier Offers Entire Collection of Journals and Books to Innovators in Developing Countries Through the Access to Research for Development and Innovation (ARDI) Program
8. Frost & Sullivan Recognizes A*STAR, Singapore with the 2012 Asia Pacific National Innovation Development Award
9. NSF awards $450,000 to UNH, Conductive Compounds Inc. for solar panel innovation
10. Tufts Medical Center Announces Inaugural INNOVATION Day: Innovating a Path to Market
11. Israeli Ministry of Finance Hosts Israel Investment, Innovation and Trade Forum in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... and PARIS , July ... Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that ... Drug Administration (FDA) rare pediatric disease priority review voucher ... for alirocumab.  The priority review voucher entitles the holder ... for an expedited 6-month review from the filing date ...
(Date:7/30/2014)... , July 30, 2014  Decision Resources ... and medical directors in the United ... of biosimilar market penetration will be the level ... (MCOs) and the expected lower cost to patients. ... biosimilars that meet their pricing expectations in order ...
(Date:7/30/2014)... , July 30, 2014  The Chicago Bears ... American Academy of Dermatology (Academy) in an effort to ... Chicago Bears will host free SPOT me™ skin cancer ... 2 at Soldier Field. SPOT me™ is an ... about the dangers and risks of skin cancer, and ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 While ... in health services research for a relatively long ... in interest regarding the use of these ‘big ... conditions. , By combining today’s powerful computer technology ... digital era, ‘big data’ holds significant promise for ...
Breaking Biology Technology:Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2
... Morria Biopharmaceuticals,Plc, a biopharmaceutical company focused on ... ICH compliant Phase II equivalent,multi-center study of MRX-4 ... given as an intranasal spray formulation., The ... allergic,rhinitis patients outside of the local allergy season. ...
... new apoA1 measurement and apoB:apoA1 ratio to its, comprehensive cholesterol ... ... heart disease, BIRMINGHAM, Ala., Nov. 6 Atherotech, ... Test in booth No. 2918 at the American Heart Association,Scientific Sessions ...
... 6 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ) ... 30, 2008, the first quarter of the,company,s fiscal year ... September 30, 2008 was $3.6 million, compared to $3.9 ... expenses were $6.8 million,for the first quarter of fiscal ...
Cached Biology Technology:Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients 2Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients 3Atherotech to Exhibit VAP(R) Cholesterol Test at American Heart Association Scientific Sessions 2008 2Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results 2Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results 3Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results 4Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results 5
(Date:7/30/2014)... reversible epigenetic processes to regulate its genes, and adapt ... picture of the genome regulation taking place in the ... Genome Biology and illustrates how the truffle deals ... The authors say this may shed light on how ... truffles (Tuber melanosporum), also known as Prigord truffles, have ...
(Date:7/30/2014)... the potential effects of climate change on the ... the wrong factors, according to a new paper ... Society, University of Queensland, and other organizations. The ... is missing the point when it comes to ... climate change scientists focus on the "direct" threats ...
(Date:7/30/2014)... a joint venture between The University of Texas at ... Science Center at San Antonio, has selected the winners ... Boice from UTSA and Lei Huang from the Health ... "Novel engineered ferritins for tracking and protecting neural stem ... is focused on finding a treatment for stroke through ...
Breaking Biology News(10 mins):How black truffles deal with the jumpers in their genome 2Conservation scientists asking wrong questions on climate change impacts on wildlife 2
... The Missouri Botanical Garden in St. Louis, Mo. ... of China,s botanical institutions in an effort to promote ... beneficial agreement between the Missouri Botanical Garden and the ... of Botany calls for the exchange of herbarium specimens, ...
... the University of Georgia have developed a "super strain" ... pine -- one of the most common species of ... help biofuels replace gasoline as a transportation fuel. ... such as pine, but it is a notoriously difficult ...
... GAITHERSBERG, MD, Nov. 18 As clinical studies ... promote general gastrointestinal health, a growing U.S. market1 for ... alike are recognizing the value of these beneficial microorganisms. ... directing patients to the best probiotic for their individual ...
Cached Biology News:Missouri Botanical Garden signs exchange agreement with 3 botanical institutions in China 2UGA researchers develop 'super' yeast that turns pine into ethanol 2As probiotics use grows for gut health, VSL#3 has designations for specific GI issues 2As probiotics use grows for gut health, VSL#3 has designations for specific GI issues 3
... Loading Buffer contains a precipitant to ensure that ... tracking dye to allow the user to follow ... ReddyRun™: ABgene ® s proprietary mixture ... same buffer composition used in ReddyRun™ molecular weight ...
... Insulin exerts its ... the insulin receptor, a ... of two Alpha subunits ... arranged in the following ...
... Gel loading buffer is especially formulated ... of nucleic acids. The gel loading solution ... sucrose to add density and facilitate sample ... nucleases that require divalent cations and SDS ...
... solution, Type I is ... and agarose gel electrophoresis ... offers the advantage of ... blue and xylene cyanole). ...
Biology Products: